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Can mouse genetics teach us enough about the biology of
aging to guide the search for anti-aging medicines that can
delay late-life illness? Recent progress gives reason for op-
timism, with new data showing that changes in single genes
can extend average and maximal life span by 40%. Mice
with these genetic variants remain healthy, active, and cog-
nitively intact at average ages that correspond to 110–120
years of human life span. Multiple lines of evidence now
point to a hormone, IGF-I, as a key influence on life span,
with low IGF-I levels associated with extended longevity in
multiple model systems. The goal of this research is not gene
therapyFwe have no idea of what genes to change, how to
change them, or what harm such changes might doFbut
instead to use insights from the cell biology and endocrino-
logy of genetically long-lived mice and other species to help
develop drugs that manipulate aging and thus postpone the
many diseases and disabilities that are typically trouble-
some in old age. The complete conquest of cancer or heart
disease would each lead to an increase of a mere 3% in
mean life span in humans, i.e. about a tenth of what can be
accomplished, today, in laboratory animals of delayed ag-
ing. In this context the paltry commitment to research in
biological gerontology (six cents per $100 of NIH funding,
for example) seems worth reconsideration. J Am Geriatr
Soc 53:S284–S286, 2005.
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The issue for me is what mouse geneticists can tell usabout aging and what we could potentially, some day,
do about it. Geneticists can take three approaches to aging.
They can study variations in genes among individuals or
groups to see whether they modify the aging process. They
can study races or breeds or subpopulations like Labrador
retriever dogs and Chihuahua dogs to see how they differ in
aging, and they can evaluate rare mutations that influence
the aging process. The experiments we do in our laboratory
start with a population we call UM-HET3 mice. Basically
we have a family of 1,800 animals that are all brothers and
sisters. Every animal of our population shares half of its
genes with every other animal in the population. We can
analyze the DNA and genes from every mouse. Then we
measure how old each mouse gets, how quickly, what dis-
eases it has, whether it has cognitive problems or cataracts,
and we just match the two sets of information to try to find
how many genes there are that influence these processes,
what those genes do, and where they are located.
Some of these genes act early in life to make animals get
old fast and others act only late in life to make old age a
more severe event.1 There are genes that act early in life in
young adulthood to change traits. But, in the same mice,
there are other genes that affect the same traits and do it in a
way that cannot be detected in young adults, and only be-
comes apparent when the mice are middle aged or older.
These genes affect the same traits, but they act later in life.
When we start to tease apart the genes that affect aging in
humans, we need to think about this. We need to be able to
test people at several ages during their life spans to see
which genes are affecting them early on and which genes are
affecting them later. We have found genetic differences in a
very wide range of age-sensitive traits, including bones,
eyes, hormones, weight, what they die of. Are there any
genes in these mice that influence the age at which they die?
The answer is yes. For instance, there are a pair of genes on
chromosomes 2 and 16; if the mouse is lucky enough to get
the good ones, it lives 173 days longer than mice unlucky
enough to get the bad ones. This is a big effect, several times
larger than the effect you would see in the human population
if you cured cancer, heart disease, stroke, and diabetes. We
then looked at mice that died of cancer because we wanted
to see if these genes affect the age at which cancer occurred,
and the answer is yes.2 We also looked at those mice in the
population that died of something other than cancer. We
wanted to know if the genes affect those diseases, too, and,
again, the answer was yes with a similar-sized effect. So, our
take home message was that there were genetic processes
that influence the rate at which mice age, that is the like-
lihood of becoming a healthy old mouse, regardless of which
diseases are likely to develop. This kind of evidence suggests
that there might well be a specific aging process that we can
learn enough about to modify or prevent.
The same kind of information allows us to investigate
the idea that the rate of aging might be influenced by proc-
esses that start early in life; that turned out to be the case.
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Even as early as three months of age, we can measure
something in these mice that tells us how likely it is that they
will be in the long-lived group. It is easy; just weigh them.
The smaller, shorter, light weight animals are the ones that
live longer.3 The mice that are longer in their body length
and heavier for that reason tend to die young. Something in
the first few months of life influences the ultimate longevity
of these animals.
What is it in the first few months of mouse life, or
perhaps in the first few years of human life, that sets the
stage to allow some people to be healthy in their 80s, or to
condemn others to be unhealthy and dead in the 60s and
70s? One of the factors is likely to be the hormone insulin-
like growth factor-I (IGF-I). It is not insulin, but it is a
hormone that resembles insulin and influences the rate of
growth; in our population, those animals that have a lot of
this insulin-like growth factor tend to die relatively young.
Those animals that have a little of it are the small animals
that tend to be long lived.
Dogs are a good example.4 If you go and get a St Bern-
ard or a Wolfhound or a Great Dane, you are unlikely to
have that companion ten or twelve years later. Big dogs tend
to die young. Big dogs live, on average, about seven or eight
years. Little dogs, like Chihuahuas and West Highland
White terriers and Cairn terriers are not only light weight,
but they are very long lived. In two studies in which it has
been looked at, IGF-I appeared responsible for the differ-
ence between a breed of big dogs and a breed of little
dogs.5,6 Lower levels of IGF-I were associated with small
size and long life span as well. So, if it is true for dogs (and
also for horses), and true for mice, it is likely, I think, to be
true for people as well, that aging and life span are, in part,
influenced by early life processes that modify body growth
and body weight. We need to find out how nature does it
and see if we can do it ourselves.
To get some additional insights, we compared labora-
tory and wild mice. The laboratory mice are big, fat, be-
come sexually mature early, have big litters, but pay a price,
namely shorter life spans. The wild mice are small, have
small litters, take much longer to become sexually mature,
and have 25 percent longer life spans. We think it is quite
likely that the genes that are influencing life spans in our
experiments are genes that actually are selected for their
effects on reproduction, maturation, and growth, and that
the aging consequence is just a side effect, but how that side
effect works is what we now need to look at. We are map-
ping these genes because we can make crosses between the
wild mice and the laboratory mice, we can see that the
crosses come out right in the middle, which is good because
we can now start to tease apart which genes are involved.
Rare mutants allow us to tease apart the aging process
and the star mutant in our laboratory is the Snell dwarf
mouse which stays one-third normal size throughout its
entire adult life, and is very long lived. They live forty per-
cent longer, and this is related to a change in a single gene.7
This gene lowers IGF-I and it also lowers thyroid hormone
levels. This is consistent with the notion that changing these
hormones early in life produces a mouse that may be small
and less fertile, but has multiple advantages. As they get
older, they look younger, have excellent cognition and
learning, have excellent collagen, and resist cataract devel-
opment. Interestingly, their cells are hard to kill in vitro
with ultraviolet light, heating, herbicides, or trace metals.
We think having cells that are hard to kill is a good thing for
these mice. We think that’s why they are so long lived, so
cataract resistant, so cognitively intact, and we would like
to use this system to find out what agents can cause cells in
culture to become hard to kill, and then try to develop
pharmaceutical agents for use in animals and humans. I
would stress that these mice are not just alive longer, but
they are healthy. That is, they have good joints, good lenses,
good immunity, good cognition at ages at which the con-
trols are already dead. And the hormones early in the life
span, particularly IGF-I but also possibly thyroid hor-
mones, seem to be a key part of that process. We think those
are the causes, but the pathways connecting the hormones
to the cell biology and then to disease resistance have not yet
been defined.
Unfortunately, the things we can do in the laboratory to
play around with longevity are trivial compared to what
nature long ago figured out how to do. By caloric restric-
tion, we can get about a fifty percent increase in longevity.
That is not bad: it is better than you could do by conquering
cancer, kidney disease, heart disease, stroke, etc. But, na-
ture, even within a specific group of mammals, can do a lot
better. The shortest lived rodents differ by a factor of 10
from the longest lived rodents. The shortest lived primates
and the longest lived primates differ by a factor of about ten
or so. If we want to make any real progress in this area, I
think we need to figure out how nature does it. Closely
related species, as we all know, age at significantly different
rates. Baboons and people share about 97 percent of their
genes, and of the three percent that are different, what we as
gerontologists need to figure out is which tiny fraction of
that three percent play a major role in the aging process to
account for the fact that the baboon is likely to live about 20
years whereas humans live about 80 years. Many species
can evolve a set of genes that slow down aging of the eyes,
aging of the brain, of the immune system, aging of the
muscles, everything that is associated with aging. We do not
know whether nature always uses the same trick or not. Is it
stress resistance or low free radicals or changes in hor-
mones, better DNA repair, or other mechanisms or multiple
mechanisms acting in concert? We need to find out how
nature creates long–lived organisms.
Is there a common pathway used by caloric restriction
and genetic mechanisms to increase longevity? The data
suggest pretty strongly that, in some ways, caloric restric-
tion mechanisms overlap, not always, but in some ways,
with the dwarf mouse story. And that is interesting because
that allows us to focus on the elements of the caloric re-
striction story that actually count, the ones that actually
contribute to the longevity and the elements of the dwarf
picture that actually contribute to the life span extension.
From my point of view, what would be extraordinarily in-
teresting is to know which ones are shared across species.
Do long-lived dogs and bats, long–lived birds, naked mole
rats, and porcupines share common physiological mecha-
nisms that extend their life span?
Will genetic manipulation or genetic research help us to
derive pharmacologic agents that allow people to maximize
their physiological life span, with life expectancy at birth of
90 to 99 years? If we wear seat belts, drink just enough but
not too much, and exercise a lot, eat a lot of vegetable
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foods, this is going to help us live longer and healthier lives,
as will successful prevention or treatment of specific dis-
eases. Could genetics help out? I think genetic models that
have delayed aging like the dwarf mouse may point toward
good preventive medicine if we find that, for example, in all
of these models of aging, including those that are based on
considerations of differences among species, blocking free
radicals is the critical mechanism. That might focus even
more attention on free radical blockers than currently ex-
ists. But if the genetic models point, instead, to DNA repair,
or changes in hormone responses or something else, we’d
need to direct our attention to those pathways rather than
to free radical damage.
Will genetic manipulation or pharmacologic agents
suggested by genetic research offer a realistic possibility of
life expectancy at birth of 110 or 120 or more years?
Twenty years ago, this was a science fiction question, but no
more, and it is interesting to speculate based on current
evidence. I believe the answer is yes. We know that we can
do this in mice and in rats, we know that by changing a
single gene or by a modest dietary alteration, we can create
healthy, cognitively intact, vigorous animals that live forty
percent longer. That does not prove we can do it in humans,
and, of course, it does not tell us how we can do it in hu-
mans, but it is no longer irresponsible to suggest that it
could be done. Indeed, we ought to figure out how to do it
because it’s a good thing to do. I do not believe genetic
manipulation is part of the answer. I do not think there’s any
rational basis now other than science fiction for thinking
that we are going to get that far by fixing people’s genes. We
do not know what genes they are, and we do not know
whether fixing them would be a good or bad thing, and we
certainly do not know how to do it. So, this is not a genetic
change story. Rather, it is a matter of using genetic research
to learn about how the cells work and how the body works,
and then designing pharmacological agents that make use
of our genetic information to slow aging down. I think that
is a realistic possibility. How far are we from achieving this
goal? The answer is again speculation. The answer I would
give is we are closer to this than we are to eliminating cancer
or heart attacks. Of the hundred dollars spent by our gov-
ernment on medical research, six cents are spent on biology
of aging. I think that’s a mistake because we’re not going to
cure cancer in the next twenty years, we’re not going to cure
heart attacks or strokes, but given adequate resources, and
given adequate numbers of dedicated scientists working on
this, we have a realistic possibility of learning how to do
something about aging, not to cure it, but to slow it down in
medically important ways. Nearly all deaths from cancer,
strokes, heart attacks and many other important illnesses
occur in old age, and thus progress on practical ways to
retard aging is likely to bring with it major retardation of all
these forms of illness. To make real progress on this, so that
you will be living longer, requires wisdom, a commitment of
substantial dollars for research, and, of course, as usually is
the case, some luck. Our goal is to find ways to allow adults
who are already healthy and productive in their 50s and 60s
to remain so for another three or four decades instead of
one or two decades.
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